Emergent BioSolutions (EBS) Misses Q2 EPS by 137c; offers guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.28 -1.19%
Revenue Growth %: +32.0%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
CRMT, FOMI, FLES, More
Revenue Growth %: +32.0%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($2.32), $1.37 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $254.7 million versus the consensus estimate of $190 million.
GUIDANCE
Emergent BioSolutions sees FY2024 revenue of $1.050 - $1.125 billion versus the consensus of $1.033 billion
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- US Foods wins $43.6M Defense Logistics contract extension
- Whirlpool to close Mexico plant, expects $165M restructuring cost
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
